CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

Journal of Neural Transmission

Volumn 112, Issue 4, 2005, Pages 519-537

  Youdim, M B H ^a   Buccafusco, J J ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylcholinesterase; Age associated memory impairment; Alzheimer's disease; Amyloid beta peptide; Amyloid precursor protein; Delayed matching to sample; Monoamine oxidase; Nerve growth factor; Parkinson's disease

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; [3 [[[2 [(5 DIMETHYLAMINOMETHYL) 2 FURANYL]METHYL]THIO]ETHYL]AMINO] 4 NITROPYRIDAZINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIOXIDANT; CHELATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPYRRONIUM BROMIDE; HEXAMETHONIUM; JWS USC 75IX; LADOSTIGIL; MECAMYLAMINE; MEMANTINE; METHYLATROPINE; MILAMELINE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE; RASAGILINE; RIVASTIGMINE; RS 17017; RS 56812; RS 66331; SELEGILINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TACRINE; TV 3294; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; DRUG MECHANISM; HUMAN; MEMORY; METABOLISM; MOLECULE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DRUG DESIGN; HUMANS; NEUROPHARMACOLOGY; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; NOOTROPIC AGENTS; PARKINSON DISEASE; RECEPTORS, NEUROTRANSMITTER;

EID: 17644375125     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0214-z     Document Type: Review

References (70)

1. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434: 109-116
2. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MBH, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82: 913-923
3. Areosa SA, Sherriff F (2003) Memantine for dementia. Cochrane Database of Systematic Reviews 1: CD003154
4. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB (2004) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89(5): 1119-1125
5. Bechara A, Tranei D, Damasio H, Adolphs R, Rockland C, Damasio AR (1995) Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippo-campus in humans. Science 269: 1115-1118
6. Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36: 303-326
7. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing anti-depressant activity? Psychopharmacology 94: 147-160
8. Buccafusco JJ (1984) Inhibition of regional brain acetylcholine biosynthesis by clonidine in spontaneously hypertensive rats. Drug Dev Res 4: 627-633
9. Buccafusco JJ (1992) Neuropharmacologic and behavioral actions of clonidine: interactions with central neurotransmitters. Int Rev Neurobiol 33: 55-107
10. Buccafusco JJ, Terry AV Jr (2000) Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295: 438-446
11. Buccafusco JJ, Prendergast M, Terry AV Jr, Jackson WJ (1996) Cognitive effects of nicotinic cholinergic agonists in non-human primates. Drug Dev Res 38: 196-203
12. Buccafusco JJ, Terry AV Jr, Goren T, Blaugrun E (2003) Potential cognitive actions of TV3326, a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 119: 669-678
13. Callahan MJ (1999) Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys. Psychopharmacology 144: 234-238
14. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MBH (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585
15. Cassel JC, Jeltsch H (1995) Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69: 1-41
16. Corey-Bloom J (2003) Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract 57: 219-223
17. Davidson M, Bierer LM, Kaminsky R, Ryan TM, Davis KL (1989) Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord 3: 224-227
18. Doraiswamy PM (2002) Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 16: 811-824
19. Eichenbaum H (1997) How does the brain organize memories. Science 277: 330-332
20. Elrod K, Buccafusco JJ (1988) An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols. J Pharmacol Biochem Behav 29: 15-21
21. Elrod K, Buccafusco JJ, Jackson WJ (1988) Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43: 277-287
22. Engelborghs S, De Deyn PP (1997) The neurochemistry of Alzheimer's disease. Acta Neurol Belg 97: 67-84
23. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147
24. Gilbert PE, Kesner RP, DeCoteau WE (1998) Memory for spatial location: role of the hippocampus in mediating spatial pattern separation. J Neurosci 18: 804-810
25. Green RC (1995) Alzheimer's disease and other dementing disorders in adults. Clin Neurol 3: 1-83
26. Haroutunian V, Kanof PD, Tsuboyama G, Davis KL (1990) Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res 507: 261-266
27. Huang W, Chen Y, Shohami E, Weinstock M (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 366: 127-135
28. Jackson WJ, Buccafusco JJ (1991) Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol Biochem Behav 39: 79-84
29. Knowlton BJ, Mangels JA, Squire LR (1996) A neostriatal habit learning system in humans. Science 273: 1399-1402
30. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589-590
31. Maruyama W, Skao Y, Youdim MBH, Naoi M (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-[ropargylamines-1(R)- and (S)-aminoindan, rasagiline and TVP1022. Adv Res Neurodegeneration 8: 171-187
32. Maruyama W, Youdim MBH, Naoi M (2001a) Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV 1022. Ann NY Acad Sci 939: 320-329
33. Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M (2001b) Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 108: 11-24
34. Maruyama W, Akao Y, Carrillo M, Kitani K, Youdium M, Naoi M (2002a) Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24: 675-682
35. Maruyama W, Takahashi T, Youdim MBH, Naoi M (2002b) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109: 467-481
36. Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]- ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341(3): 233-236
37. Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L (1991) Very mild Alzheimer's disease: informant based clinical, psychometric, and pathologic distinction from normal aging. Neurology 41: 469-478
38. Myhrer T (1998) Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Neurosci Biobehav Rev 23: 131-139
39. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59(12): 1937-1943
40. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61(4): 561-566
41. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57: 201-210
42. Riedel G, Micheau J, Lam AGM, Roloff EvL, Martin SJ, Bridge H, de Hoz L, Poeschel B, McCulloch J, Morris RGM (1999) Reversible neural inactivation reveals hippocampal participation in several memory processes. Nat Neurosci 2: 898-905
43. Sagi Y, Weinstock M, Youdim MBH (2003) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 86: 290-297
44. Speiser Z, Levy R, Cohen S (1998) Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm [Suppl] 52: 287-300
45. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB, Weinstock M (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45: 5260-5279
46. Sybirska E, Davachi L, Goldman-Rakic PS (2000) Prominance of direct entorhinal-CA 1 pathway activation in sensorimotor and cognitive tasks revealed by 2-DG functional mapping in nonhuman primates. J Neurosci 20: 5827-5834
47. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317-324
48. Teng E, Stefanacei L, Squire LR, Zola SM (2000) Contrasting effects on discrimination learning after hippocampal lesions and conjoint hippocampal-caudate lesions in monkeys. J Neurosci 20: 3853-3863
49. Terry AV Jr, Jackson WJ, Buccafusco JJ (1993) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 3: 304-312
50. Terry AV Jr, Gattu M, Buccafusco JJ, Sowell JW, Kosh JW (1999) Ranitidine analog, JWS-USC-75IX, enhances memory-related task performance in rats. Drug Dev Res 47: 97-106
51. Vann SD, Brown MW, Erichsen JT, Aggleton JP (2000) Fos imaging reveals differential patterns of hippocampal and parahippocampal subfield activation in rats in response to different spatial memory tests. J Neurosci 20: 2711-2718
52. Vargha-Khadem F, Gadian DG, Watkins KE, Connelly A, Van Paesschen W, Mishkin M (1997) Science 277: 376-380
53. Weinreb O, Bar-Am O, Chillag-Talmor O, Youdim MBH, Amit T (2004) Neuroprotection via pro-survival PKC isoforms associated with Bcl-2 members. FASEB J 18: 1471-1474
54. Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JPM, Youdim MBH (2000a) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm [Suppl] 60: 157-169
55. Weinstock M, Goren T, Youdim MBH (2000b) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50: 216-222
56. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MBH, Shoham S (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann NY Acad Sci 939: 148-162
57. Weinstock M, Poltyrev T, Bejar C, Youdim MB (2002) Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 160: 318-324
58. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 27(4): 555-561
59. Weiser T (2004) Drugs that target ionotropic excitatory amino acids. In: Buccafusco JJ (ed) Cognitive enhancing drugs. Birkhäuser, Basel, pp 89-96
60. Wu M, Shanabrough M, Leranth C, Alreja M (2000) Cholinergic excitation of septohippocampal GABA but not cholinergic neurons: implications for learning and memory. J Neurosci 20: 3900-3908
61. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB (2002) Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16: 1674-1676
62. Yogev-Falach M, Amit T, Bar-Am O, Youdim MB (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 17(15): 2325-2327
63. Youdim MBH (1989) Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter-producing enzyme. Prog Neuropsychopharmacol Biol Psychiatry 13: 363-371
64. Youdim MB, Riederer P (1993) Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm (Gen Sect) 91: 181-195
65. Youdim MBH, Weinstock M (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Biol 21: 555-573
66. Youdim MB, Weinstock M (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123: 1081-1086
67. Youdim MBH, Gross A, Finberg JP (2001a) Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506
68. Youdim MBH, Wadia A, Tatton W, Weinstock M (2001b) The anti-parkinson drug rasagiline and its derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 931: 450-459
69. Youdim MBH, Amit T, Falach-Yogev M, Bar-Am O, Maruyama W, Naoi M (2003) The essentiality of Bcl-2, PKc and proteasome-ubiquitin complex activation in the neuroprotective action of antiparkinson drug, rasdagiline. Biochem Pharmacol 66: 1635-1641
70. Zola SM, Squire LR, Teng E, Stefanacei L, Buffalo EA, Clark RE (2000) Impaired recognition memory in monkeys after damage limited to the hippocampal region. J Neurosci 20: 451-463